Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relay Therapeutics

2.65
-0.1150-4.17%
Volume:613.01K
Turnover:1.62M
Market Cap:448.39M
PE:-1.12
High:2.74
Open:2.72
Low:2.57
Close:2.76
Loading ...

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey
·
1 hour ago

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

Insider Monkey
·
31 Mar

Relay Therapeutics weakness brings buying opportunity, says Barclays

TIPRANKS
·
30 Mar

Relay Therapeutics weakness brings buying opportunity, says Barclays

TIPRANKS
·
27 Mar

Relay Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating

TIPRANKS
·
07 Mar

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

Zacks
·
05 Mar

Bank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments

TIPRANKS
·
28 Feb

Relay Therapeutics Is Maintained at Buy by Goldman Sachs

Dow Jones
·
28 Feb

Stock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares

Stock Track
·
27 Feb

Relay Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

TD Cowen Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
27 Feb

Relay Therapeutics reports Q4 EPS (45c), consensus (55c)

TIPRANKS
·
27 Feb

Relay Therapeutics Q4 GAAP EPS $(0.45) Beats $(0.58) Estimate

Benzinga
·
27 Feb

BRIEF-Relay Therapeutics Q4 Net Income USD -76.004 Million

Reuters
·
27 Feb

Relay Therapeutics Q4 Basic EPS USD -0.45

THOMSON REUTERS
·
27 Feb

Relay Therapeutics Q4 Operating Expenses USD 84.979 Million

THOMSON REUTERS
·
27 Feb

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

GlobeNewswire
·
27 Feb